DoD tests AI models that make it easy to switch from vendors like Palantir
NORTH CHICAGO - AbbVie Inc. (NYSE: ABBV), a pharmaceutical giant with a market capitalization of $327.65 billion, announced Friday that its board of directors has declared a quarterly cash dividend of $1.64 per share, representing a 3.54% yield.
The dividend will be payable on August 15, 2025, to stockholders of record at the close of business on July 15, 2025, according to a press release statement.
AbbVie has increased its dividend by 310 percent since the company’s formation in 2013. The pharmaceutical company is a member of the S&P Dividend Aristocrats Index, which tracks companies that have increased their dividend annually for at least 25 consecutive years.
AbbVie focuses on several therapeutic areas including immunology, oncology, neuroscience and eye care, as well as products and services in its Allergan Aesthetics portfolio.
The quarterly dividend announcement comes as part of the company’s regular financial operations and represents a continuation of its dividend payment schedule.
In other recent news, AbbVie announced that its migraine prevention drug, atogepant, showed superior results in a Phase 3 clinical trial compared to topiramate. The trial, known as the TEMPLE study, demonstrated that 64.1% of patients experienced at least a 50% reduction in monthly migraine days, with fewer patients discontinuing treatment due to adverse events. Meanwhile, AbbVie faced a setback as its Phase 3 VERONA trial for venetoclax in treating higher-risk myelodysplastic syndrome did not meet its primary endpoint of overall survival. However, no new safety concerns were reported. In a positive development, the FDA approved a label expansion for AbbVie’s MAVYRET, making it the first oral treatment for acute hepatitis C virus infection, achieving a 96% cure rate in clinical trials.
In analyst updates, Berenberg adjusted its price target for AbbVie shares, reducing it to $170 from $195, while maintaining a Hold rating. The firm highlighted the importance of AbbVie’s product, Skyrizi, in driving long-term growth. Despite the reduced price target, Berenberg noted a positive outlook for AbbVie, with emerging opportunities in oncology and a forecasted annual sales growth of 7.5% up to 2029. Additionally, the Trump administration is considering new limits on pharmaceutical advertising, which could impact the industry significantly, though no formal actions have been taken yet.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.